Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.

继 OlympiA 试验证明了生存获益之后，现在建议所有化疗后患有种系BRCA1/2致病性/可能致病性变异 (PV) 和高危 HER2 阴性早期乳腺癌的患者接受一年的奥拉帕尼辅助治疗。然而，如何最佳识别可能从这种基因组定向治疗中获益的高危患者仍存在争议。在这项研究中，我们试图根据 OlympiA 标准描述符合奥拉帕尼辅助治疗条件的gBRCA1/2 PV 携带者的真实比例，并比较符合条件和不符合条件的患者之间的临床病理特征和结果。